<DOC>
	<DOCNO>NCT02144662</DOCNO>
	<brief_summary>Primary Objective : To investigate pretreatment quantitative factor show SD-OCT image correlate posttreatment VA patient underwent intravitreal Lucentis ( Ranibizumab ) RVO . Secondary Objectives : Correlations posttreatment BCVA pretreatment factor evaluate , include age , pretreatment BCVA , photoreceptor outer segment ( PROS ) length , central foveal thickness ( CFT ) , out foveal thickness ( OFT ) , out nuclear layer thickness ( ONLT ) . The factor influence posttreatment BCVA evaluate use multiple regression analysis . Detailed information macular morphology , photoreceptor IS/OS junction ELM , obtain SD-OCT . Some OCT study evaluate quantitative factor eye disease . It report PROS length correlate BCVA patient DME.¹ Other investigator suggest thickness , area , volume outer layer correlate BCVA patient dry age-related macular degeneration ( AMD ) .² Outer foveal thickness ( OFT ) relative reflectivity outer nuclear layer ( ONL ) associate BCVA patient macular hole.3 , 4 The volume ONL find associate BCVA patient AMD.5 The aim study investigate pretreatment quantitative factor show SD-OCT image correlate posttreatment VA patient underwent intravitreal Lucentis ( Ranibizumab ) RVO .</brief_summary>
	<brief_title>Prognostic Factors Visual Improvement Patients Undergoing Intravitreal Ranibizumab Retinal Vein Occlusion</brief_title>
	<detailed_description>Detailed information macular morphology , photoreceptor IS/OS junction ELM , obtain SD-OCT . Some OCT study evaluate quantitative factor eye disease . It report PROS length correlate BCVA patient DME.¹ Other investigator suggest thickness , area , volume outer layer correlate BCVA patient dry age-related macular degeneration ( AMD ) .² OFT relative reflectivity ONL associate BCVA patient macular hole.3 , 4 The volume ONL find associate BCVA patient AMD.5 The aim study investigate pretreatment quantitative factor show SD-OCT image correlate posttreatment VA patient underwent intravitreal Lucentis ( Ranibizumab ) RVO .</detailed_description>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age ≥ 18 , Patient RVO , BCVA ≥ 0.1 ( decimal visual acuity ) , Mean VRT≥ 250 μm sign informed consent Laser photocoagulation ME ≤ 4 month prior initiation study therapy Intraocular corticosteroid use ≤ 3 month prior initiation study therapy History antiVEGF treatment ( intravitreal ≤3 month prior initiation study therapy , systemic ≤ 6 month prior initiation study therapy ) Stroke myocardial infarction ≤ 3 month prior initiation study Pregnancy potential pregnancy , breastfeed Severe liver dysfunction , severe CKD/hemodialysis , uncontrolled DM ( HbA1c &gt; 10 ) , uncontrolled hypertension ( BP≥ 160/100 mmHg )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>